Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
We see a rather positive sentiment for Palisade Bio Inc. with 6 Buy predictions and 1 Sell predictions.
With a target price of 17 € there is potential for a 4882.42% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | -1.950% | -4.598% | -21.698% | -51.682% | 10.421% | -49.527% | -93.937% |
| Pacira Pharmaceuticals | -2.200% | -6.667% | 1.676% | -24.167% | -15.741% | -54.271% | -68.889% |
| Twist Bioscience Corp | -0.630% | -3.606% | -0.958% | 5.025% | 41.077% | 120.359% | -66.703% |
Comments
Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat